This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Savage, K. J. Search for Related Content PubMed PubMed Citation Articles by Savage, K. J.

Lymphoma Series: Variants of Large-Cell Lymphoma

Primary Mediastinal Large B-Cell Lymphoma

British Columbia Cancer Agency, Vancouver, British Columbia, Canada

Correspondence: Kerry J. Savage, M.D., M.Sc., F.R.C.P.C., British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia, Canada. Telephone: 604-877-6000; Fax: 604-877-0585; e-mail: ksavage{at}bccancer.bc.ca

Primary mediastinal large B-cell lymphoma represents a distinct entity with unique clinicopathologic features and a molecular gene-expression signature reminiscent of nodular sclerosis subtype of classical Hodgkin’s lymphoma. Recent studies, including those using a refined molecular signature, suggest that the outcome is more favorable than that of diffuse large B-cell lymphoma. Using historical comparisons, dose-dense and dose-intensive regimens may be more effective than cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy; however, the impact of adding rituximab to these regimens and effect on outcome comparisons is unknown. Clinical trials exploring these questions in addition to the benefit of consolidative radiotherapy are necessary to definitively answer these questions.